Affymax, Inc. was a biopharmaceutical company based in Cupertino, CA, dedicated to developing innovative drugs for the treatment of severe and life-threatening conditions, particularly in the field of nephrology and specialty care.
With a strong commitment to delivering groundbreaking therapeutic solutions to patients and healthcare providers, Affymax aimed to establish itself as a leading player in the industry. However, following a nationwide voluntary recall of OMONTYS peginesatide Injection in February 2013, the company initiated a strategic review of alternatives in March of the same year.
Generated from the website